AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03208010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Intervention
Description: * Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~* Specific goals set for weight loss and physical activities~* Fitbits provided for monitoring physical activity goals~* Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~* 15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes.
Study NCT03208010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: * Monitoring by existing personal physicians~* Feedback on lab results~* Referrals to physicians or clinics, if needed~* Diabetes prevention educational materials
Study NCT04950647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurazone Group 1
Description: Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
Study NCT04950647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroketazine Group 2
Description: Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
Study NCT04950647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
Study NCT03827096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of human autologous MSC 3P in 1.5 ml
Description: During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
Study NCT00966134 — intervention group
Intervention type: OTHER
Intervention: exposure to high altitude
Study NCT02083900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Banana Leaf Dressing
Description: Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
Study NCT02083900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocolloid Dressing (DuoDERM CGF)
Description: The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
Study NCT01702311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedtime insulin Aspart (Novolog)
Description: Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
Study NCT00495313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: COL-101, QD plus metronidazole
Study NCT00495313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 40 mg with metronidazole QD
Study NCT04428853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iyengar yoga
Description: different yoga postures including warm up, cool down and meditation that incorporate 75 minutes of training
Study NCT02922322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Group
Description: The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
Study NCT00551811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933-AAA
Description: SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
Study NCT04660604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston Technique®
Description: Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
Study NCT04127890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ELO Water
Description: oxygen-enriched water
Study NCT04127890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drinking water
Description: bottled drinking water
Study NCT03836989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation device (tens unit)
Description: An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
Study NCT03836989 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical stimulation device (tens unit)
Description: An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
Study NCT00681746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
Study NCT00681746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C) flumazenil
Description: Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
Study NCT01249430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT01249430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01249430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT01249430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01249430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT01249430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02186223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Angel® Catheter
Description: The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
Study NCT04238065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caterna Virtual Reality
Description: Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly.
Study NCT04238065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles(Best optical corrected distance vision)
Description: Each eye has best corrected vision spectacles with best corrected optical lens.
Study NCT04238065 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacles(Best optical corrected distance vision)
Description: Each eye has best corrected vision spectacles with best corrected optical lens.
Study NCT04238065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch
Description: 2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
Study NCT04238065 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Patch
Description: 2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
Study NCT04454177 — intervention group
Intervention type: DEVICE
Intervention: HUAWEI watch
Description: HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering.
Study NCT01553097 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive impairment observation
Description: None - observational
Study NCT02804776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg oral daily for 4 weeks
Study NCT01545570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2376497
Description: GSK2376497 Active Comparator
Study NCT01545570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 0.9% sodium chloride Placebo Comparator
Study NCT04677868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
Study NCT03668353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SeV-hFGF2/dF Injection
Description: intramuscular injection of investigator drugs
Study NCT02066428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
Study NCT02066428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
Study NCT02137720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic Diabetes Self-Management Support
Study NCT02137720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Print Materials
Study NCT01470313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0360324
Description: Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
Study NCT01470313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
Study NCT01143974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed plus cisplatin
Description: pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
Study NCT02947776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
Study NCT02947776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USUAL
Description: The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
Study NCT02947776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: USUAL
Description: The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
Study NCT00234546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 1 injection, 500 U at day 0. The study will last for 6 months in each patient.
Study NCT00234546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 injection at day 0. The study will last for 6 months in each patient.
Study NCT02715154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
Study NCT02715154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
Study NCT03111251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider assessment and feedback
Description: Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
Study NCT03111251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider reminders
Description: An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
Study NCT03111251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider education
Description: Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
Study NCT03111251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reminders
Description: Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
Study NCT03111251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent education
Description: The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
Study NCT05040477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy Technique
Description: Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy.
Study NCT05040477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy Technique
Description: Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy.
Study NCT02855424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the low-intensity exercise group
Description: Totally 20-time training, frequency 2-6 time/week, total 20 times.
Study NCT02855424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the moderate-intensity exercise group
Description: Totally 20-time training, frequency 2-6 time/week,total 20 times.
Study NCT02079610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback: Amygdala
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
Study NCT02079610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: real-time fMRI neurofeedback: HIPS
Description: Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
Study NCT02482870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
Study NCT02482870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision video laryngoscope
Description: Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
Study NCT01620255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
Study NCT01620255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study NCT01620255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study NCT01620255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study NCT01620255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study NCT04508231 — intervention group
Intervention type: OTHER
Intervention: Gender-affirming hormone therapy
Description: Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
Study NCT05787028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Description: Take one AD16 tablet in the morning
Study NCT05787028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Description: Participants will take a placebo pill matching AD16 once in the morning